Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells

Muluhngwi Penn; Krishna Abirami; Vittitow Stephany L.; Napier Joshua T.; Richardson Kirsten M.; Ellis Mackenzie; Mott Justin L.; Klinge Carolyn M.

首页> 外文期刊>Cancer letters >Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells

【24h】

Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells

机译：Tamoxifen差异地调节miR-29b-1和miR-29a表达，取决于乳腺癌细胞的内分泌敏感性

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Endocrine-resistance develops in similar to 40% of breast cancer patients after tamoxifen (TAM) therapy. Although microRNAs are dysregulated in breast cancer, their contribution to endocrine-resistance is not yet understood. Previous microarray analysis identified miR-29a and miR-29b-1 as repressed by TAM in MCF-7 endocrine-sensitive breast cancer cells but stimulated by TAM in LY2 endocrine-resistant breast cancer cells. Here we examined the mechanism for the differential regulation of these miRs by TAM in MCF-7 versus TAM-resistant LY2 and LCC9 breast cancer cells and the functional role of these microRNAs in these cells. Knockdown studies revealed that ER alpha is responsible for TAM regulation of miR-29b-1/a transcription. We also demonstrated that transient overexpression of miR-29b-1/a decreased MCF-7, LCC9, and LY2 proliferation and inhibited LY2 cell migration and colony formation but did not sensitize LCC9 or LY2 cells to TAM. Furthermore, TAM reduced DICER1 mRNA and protein in LY2 cells, a known target of miR-29. Supporting this observation, anti-miR-29b-1 or anti-miR-29a inhibited the suppression of DICER by 4 -OHT . These results suggest miR-29b-1/a has tumor suppressor activity in TAM-resistant cells and does not appear to play a role in mediating TAM resistance. (C) 2016 Elsevier Ireland Ltd. All rights reserved.

机译：内分泌抵抗在他莫昔芬（TAM）治疗后类似于40％的乳腺癌患者。虽然MicroRNA在乳腺癌中具有疑虑，但尚未理解它们对内分泌抵抗的贡献。以前的微阵列分析确定了在MCF-7内分泌敏感乳腺癌细胞中被TAM抑制的miR-29a和miR-29b-1，但是在Ly2内分泌抗性乳腺癌细胞中受到刺激。在这里，我们检查了TAM在MCF-7与TAM抗性Ly2和LCC9乳腺癌细胞中对这些miR的差异调节的机制以及这些微稻草在这些细胞中的功能作用。敲低的研究表明，ERα负责MIR-29B-1 / A转录的TAM调节。我们还证明了MIR-29B-1 / A降低的MCF-7，LCC9和LY2增殖和抑制LY2细胞迁移和菌落形成的瞬时过度表达，但并未将LCC9或LY2细胞对TAM敏化。此外，TAM在Ly2细胞中减少了Dicer1 mRNA和蛋白质，是miR-29的已知靶。支持该观察结果，抗miR-29b-1或抗miR-29a抑制了4 -oht的抑制剂。这些结果表明MIR-29B-1 / A具有抗肿瘤细胞中的肿瘤抑制活性，并且似乎在介导的TAM抗性中发挥作用。（c）2016 Elsevier Ireland Ltd.保留所有权利。

著录项

来源
《Cancer letters》 |2017年第2017期|共9页
作者
Muluhngwi Penn; Krishna Abirami; Vittitow Stephany L.; Napier Joshua T.; Richardson Kirsten M.; Ellis Mackenzie; Mott Justin L.; Klinge Carolyn M.;
展开▼
作者单位

Univ Louisville Sch Med Dept Biochem &

Mol Genet Ctr Genet &

Mol Med Louisville KY 40292 USA;

Univ Louisville Sch Med Dept Biochem &

Mol Genet Ctr Genet &

Mol Med Louisville KY 40292 USA;

Univ Louisville Sch Med Dept Biochem &

Mol Genet Ctr Genet &

Mol Med Louisville KY 40292 USA;

Univ Louisville Sch Med Dept Biochem &

Mol Genet Ctr Genet &

Mol Med Louisville KY 40292 USA;

Univ Louisville Sch Med Dept Biochem &

Mol Genet Ctr Genet &

Mol Med Louisville KY 40292 USA;

Univ Louisville Sch Med Dept Biochem &

Mol Genet Ctr Genet &

Mol Med Louisville KY 40292 USA;

Univ Louisville Sch Med Dept Biochem &

Mol Genet Ctr Genet &

Mol Med Louisville KY 40292 USA;

Univ Louisville Sch Med Dept Biochem &

Mol Genet Ctr Genet &

Mol Med Louisville KY 40292 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
miRNA-29b-1; miRNA-29a; Breast cancer; Endocrine-resistance; Estrogen receptor; Tamoxifen;

机译：miRNA-29B-1;miRNA-29a;乳腺癌;内分泌抵抗;雌激素受体;Tamoxifen;

相似文献

外文文献
中文文献
专利

1. Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells [J] . Muluhngwi Penn, Krishna Abirami, Vittitow Stephany L., Cancer letters . 2017,第期

机译：Tamoxifen差异地调节miR-29b-1和miR-29a表达，取决于乳腺癌细胞的内分泌敏感性
2. Estrogen receptor alpha 46 is reduced in tamoxifen resistant breast cancer cells and re-expression inhibits cell proliferation and estrogen receptor alpha 66-regulated target gene transcription. [J] . Klinge CM, Riggs KA, Wickramasinghe NS, Molecular and Cellular Endocrinology . 2010,第2期

机译：在他莫昔芬耐药的乳腺癌细胞中雌激素受体α46降低，并且再表达抑制细胞增殖和雌激素受体α66调节的靶基因转录。
3. Oestrogen receptor-regulated glutathione S-transferase mu 3 expression attenuates hydrogen peroxide-induced cytotoxicity, which confers tamoxifen resistance on breast cancer cells [J] . Juo-Han Lin, Shih-Hsin Tu, Li-Ching Chen, Breast cancer research and treatment. . 2018,第1期

机译：雌激素受体调节的谷胱甘肽S-转移酶MU 3表达衰减过氧化氢诱导的细胞毒性，其将他莫氧基抗性对乳腺癌细胞的抗性赋予
4. An iTRAQ-RPLC-MS/MS approach for protein differential expression profiling of MCF7 breast cancer cells: Towards biomarker discovery [C] . Jenny M. Armenta, Iulia M. Lazar ASMS Conference on Mass Spectrometry and Allied Topics . 2008

机译：MCF7乳腺癌细胞蛋白质差异表达分析的ITRAQ-RPLC-MS / MS方法：迈向生物标志物发现
5. Tamoxifen regulation of angiogenesis-related and proinflammatory cytokine and receptor gene expression in THP-1-derived macrophages and MCF-7 breast cancer cells. [D] . Morris, Gay Sherrell. 2004

机译：他莫昔芬对THP-1衍生的巨噬细胞和MCF-7乳腺癌细胞中血管生成相关和促炎性细胞因子及受体基因表达的调节。
6. Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells [O] . Penn Muluhngwi, Abirami Krishna, Stephany L. Vittitow, -1

机译：他莫昔芬根据乳腺癌细胞的内分泌敏感性差异调节miR-29b-1和miR-29a表达
7. Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells [O] . Penn Muluhngwi, Abirami Krishna, Stephany L. Vittitow, 2017

机译：Tamoxifen差异地调节miR-29b-1和miR-29a表达，取决于乳腺癌细胞的内分泌敏感性

Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells

摘要

著录项

相似文献

相关主题

期刊订阅